News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,994 Results
Type
Article (43938)
Company Profile (474)
Press Release (698566)
Multimedia
Podcasts (132)
Webinars (23)
Section
Business (209513)
Career Advice (2042)
Deals (36188)
Drug Delivery (128)
Drug Development (84055)
Employer Resources (174)
FDA (16753)
Job Trends (15209)
News (354544)
Policy (33313)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2679)
Accelerated approval (45)
Adcomms (29)
Allergies (165)
Alliances (51131)
ALS (202)
Alzheimer's disease (1800)
Antibody-drug conjugate (ADC) (387)
Approvals (17036)
Artificial intelligence (626)
Autoimmune disease (230)
Automation (50)
Bankruptcy (374)
Best Places to Work (11845)
BIOSECURE Act (20)
Biosimilars (205)
Biotechnology (332)
Bladder cancer (182)
Brain cancer (67)
Breast cancer (700)
Cancer (5427)
Cardiovascular disease (464)
Career advice (1731)
Career pathing (40)
CAR-T (308)
CDC (55)
Celiac Disease (2)
Cell therapy (834)
Cervical cancer (41)
Clinical research (72102)
Collaboration (1985)
Company closure (4)
Compensation (1275)
Complete response letters (80)
COVID-19 (2787)
CRISPR (107)
C-suite (1007)
Cystic fibrosis (156)
Data (7118)
Decentralized trials (3)
Denatured (42)
Depression (163)
Dermatology (58)
Diabetes (552)
Diagnostics (6889)
Digital health (51)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (309)
Drug pricing (203)
Drug shortages (30)
Duchenne muscular dystrophy (284)
Earnings (92389)
Editorial (63)
Employer branding (21)
Employer resources (153)
Events (122131)
Executive appointments (1062)
FDA (20194)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1673)
Gene editing (230)
Generative AI (52)
Gene therapy (709)
GLP-1 (1059)
Government (4793)
Grass and pollen (6)
Guidances (397)
Healthcare (19257)
HIV (75)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (297)
Immuno-oncology (86)
Indications (156)
Infectious disease (3105)
Inflammatory bowel disease (211)
Inflation Reduction Act (17)
Influenza (131)
Intellectual property (277)
Interviews (316)
IPO (16945)
IRA (53)
Job creations (3716)
Job search strategy (1441)
JPM (67)
Kidney cancer (18)
Labor market (92)
Layoffs (587)
Leadership (36)
Legal (8033)
Liver cancer (99)
Longevity (28)
Lung cancer (729)
Lymphoma (411)
Machine learning (53)
Management (59)
Manufacturing (925)
MASH (184)
Medical device (14017)
Medtech (14094)
Mergers & acquisitions (20393)
Metabolic disorders (1458)
mRNA (198)
Multiple sclerosis (177)
NASH (20)
Neurodegenerative disease (407)
Neuropsychiatric disorders (104)
Neuroscience (3250)
Neurotech (1)
NextGen: Class of 2026 (6776)
Non-profit (4598)
Now hiring (73)
Obesity (699)
Opinion (298)
Ovarian cancer (185)
Pain (233)
Pancreatic cancer (259)
Parkinson's disease (352)
Partnered (34)
Patents (555)
Patient recruitment (598)
Peanut (61)
People (60671)
Pharmaceutical (81)
Pharmacy benefit managers (32)
Phase 1 (22676)
Phase 2 (31800)
Phase 3 (23498)
Pipeline (7086)
Policy (319)
Postmarket research (2602)
Preclinical (9685)
Press Release (67)
Prostate cancer (282)
Psychedelics (57)
Radiopharmaceuticals (321)
Rare diseases (1051)
Real estate (6071)
Recruiting (71)
Regulatory (25470)
Reports (54)
Research institute (2504)
Resumes & cover letters (355)
Rett syndrome (32)
RNA editing (22)
RSV (85)
Schizophrenia (167)
Series A (283)
Series B (210)
Service/supplier (11)
Sickle cell disease (114)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (46)
Startups (3817)
State (2)
Stomach cancer (19)
Supply chain (118)
Tariffs (85)
The Weekly (87)
Vaccines (1086)
Venture capital (106)
Weight loss (447)
Women's health (111)
Worklife (20)
Date
Today (123)
Last 7 days (660)
Last 30 days (2857)
Last 365 days (30979)
2026 (7884)
2025 (31073)
2024 (36298)
2023 (41021)
2022 (52291)
2021 (56774)
2020 (54950)
2019 (47445)
2018 (35728)
2017 (33042)
2016 (32366)
2015 (38450)
2014 (32207)
2013 (27118)
2012 (29230)
2011 (29868)
2010 (28002)
Location
Africa (756)
Alabama (94)
Alaska (7)
Arizona (337)
Arkansas (15)
Asia (40944)
Australia (6802)
California (12440)
Canada (3516)
China (1260)
Colorado (530)
Connecticut (539)
Delaware (366)
Europe (89946)
Florida (1849)
Georgia (396)
Hawaii (3)
Idaho (62)
Illinois (980)
India (79)
Indiana (561)
Iowa (24)
Japan (490)
Kansas (133)
Kentucky (46)
Louisiana (39)
Maine (73)
Maryland (1502)
Massachusetts (8998)
Michigan (347)
Minnesota (683)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (134)
New Hampshire (87)
New Jersey (3323)
New Mexico (31)
New York (3252)
North Carolina (1632)
North Dakota (9)
Northern California (6128)
Ohio (366)
Oklahoma (22)
Oregon (44)
Pennsylvania (2492)
Puerto Rico (25)
Rhode Island (51)
South America (1127)
South Carolina (74)
South Dakota (1)
Southern California (4865)
Tennessee (200)
Texas (1935)
United States (44147)
Utah (370)
Vermont (1)
Virginia (297)
Washington D.C. (81)
Washington State (1019)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
742,994 Results for "858 therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer
January 8, 2026
·
2 min read
Business
858 Therapeutics Expands Leadership Team to Support Transition to the Clinic
858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.
December 20, 2023
·
2 min read
Drug Development
858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting
858 Therapeutics today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
March 14, 2024
·
2 min read
Press Releases
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
March 10, 2026
·
5 min read
Press Releases
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
March 25, 2026
·
5 min read
Press Releases
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
March 24, 2026
·
5 min read
Press Releases
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 9, 2026
·
9 min read
Press Releases
858 Therapeutics and OpenBench Launch Small Molecule Drug Discovery Collaboration
November 4, 2024
·
2 min read
Press Releases
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 9, 2026
·
5 min read
Press Releases
858 Therapeutics Announces $50 Million Series B Financing
September 27, 2024
·
3 min read
1 of 74,300
Next
